Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced today the partition of Concortis Biosystems into two separate companies, Concortis Biotherapeutics and Levena Biopharma.
The breakup into two business lines will allow Concortis Biotherapeutics to focus on development of "first-in-class" and "best-in-class" antibody drug conjugates (ADCs) to address significant unmet medical need. The new web site (www.concortis.com) is under construction and will be available soon.
By integrating current Concortis ADC service business with additional large-scale and cGMP manufacturing capability, Levena Biopharma will offer the antibody community a broad range of ADC services from the initiation of an ADC project through cGMP manufacturing of ADCs to phase I/II clinical studies. For detail information, please visit www.levena.com.